Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity and Common Stock Purchase Warrants - Schedule of Noncontrolling Interest (Details)

v3.19.2
Stockholders' Equity and Common Stock Purchase Warrants - Schedule of Noncontrolling Interest (Details) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Dec. 31, 2018
NCI - equity (deficit) - beginning of period     $ (161,512)    
Net loss attributable to NCI $ (145,522) $ (81,200) (314,273) $ (81,200)  
NCI - equity (deficit) - end of period (342,727)   (342,727)   $ (161,512)
Noncontrolling Interest [Member]          
NCI - equity (deficit) - beginning of period     (161,512)
Investment in majority-owned subsidiary       1,812
Net loss attributable to NCI     (314,273)   (204,072)
Lucid Diagnostics Inc. 2018 Equity Plan - stock-based compensation     133,058   40,748
NCI - equity (deficit) - end of period $ (342,727)   $ (342,727)   $ (161,512)